KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.

P2860

KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.

Item

http://www.wikidata.org/entity/Q38854561

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

KRAS exon 2 mutations influenc ...... se model of colorectal cancer.

@en

type

Item

label

KRAS exon 2 mutations influenc ...... se model of colorectal cancer.

@en

prefLabel

KRAS exon 2 mutations influenc ...... se model of colorectal cancer.

@en

P1433

Q38854561-E345F8E1-FB77-417B-960D-9901446A49EC

P1476

Q38854561-FF56A878-3BEE-4826-BF51-EE2C6091B7B3

P2093

Q38854561-0254A27C-7E8F-4743-8371-C11138247E0E

Q38854561-043259EA-AA85-4CEC-924B-FAB09E44FDDC

Q38854561-09BE8E42-3C85-4961-B395-0BA0D0738AFE

Q38854561-14F3BEE0-4415-4487-9A61-9EF37BAF1CEA

Q38854561-1CA5F554-2E30-4909-BF56-0EE5A5EB4F0E

Q38854561-20A9EDD0-5B12-48E6-8BA1-16C5596C1384

Q38854561-6D0A5F96-F6C1-4A3D-A4BC-10AAEBE7F504

Q38854561-6D422363-3B96-4866-85FD-A86781A0C084

Q38854561-6E7DA42E-4BE8-4B14-838C-2B5C446B5BE2

Q38854561-974C666A-B5C9-4E6E-9401-D411FF288141

P2860

Q38854561-2D812ABF-2F09-475C-BABD-B57D77AC1B35

Q38854561-33EB7FEF-9B0D-452B-837B-E59C24F71E6F

Q38854561-3D604693-C854-47FD-A900-A640D13E1FDE

Q38854561-5C28BB75-3D30-4F22-AFFD-960A57602038

Q38854561-5F1F0E03-EDEF-423F-B9E5-60A2932A4B8B

Q38854561-6CC54A7D-BB8F-47C6-B4D2-E3A35807F791

Q38854561-969C2BD4-E8CB-4EC0-8967-35223C820024

Q38854561-97317126-0EB2-4308-966E-4E296C402DB7

Q38854561-98152492-2239-4B4E-A515-B83E658CAA97

Q38854561-A099E197-1879-4FA1-A069-B2D798848D71

P304

Q38854561-8D91D01A-EB83-432A-8F6A-73B7D735A483

P31

Q38854561-23A2CA93-9973-49D6-99AA-5C989D9AB97A

P356

Q38854561-22A1CCFA-88C4-4F92-A37D-C597A4221FCB

P407

Q38854561-B8FC31B7-93FE-416B-AA4D-FE75F1430F88

P433

Q38854561-3CD003DC-9885-403A-963C-18C198B5EC06

P478

Q38854561-CCC2D134-9AAB-430D-86A1-D70C9BA6D049

P50

Q38854561-F8DB5321-9E80-473D-A027-7D1588F4F0A7

P577

Q38854561-2B3F5B4C-7B23-4657-88EA-0C1CAA10E069

P5875

Q38854561-EFF860DC-C896-4CF0-BE93-17234C1F1C61

P698

Q38854561-707F855C-29E6-4E7E-80E6-76892D2EA4B5

P921

Q38854561-603373D5-1AF8-484E-A883-9B981EFA1806

P356

FON.15.97

P1433

Future Oncology

P1476

KRAS exon 2 mutations influenc ...... se model of colorectal cancer.

@en

P2093

Andreas Jung

http://www.w3.org/2001/XMLSchema#string

Christiane Josephine Bruns

http://www.w3.org/2001/XMLSchema#string

Clemens Giessen-Jung

http://www.w3.org/2001/XMLSchema#string

Dominik Paul Modest

http://www.w3.org/2001/XMLSchema#string

Peter Camaj

http://www.w3.org/2001/XMLSchema#string

Ruediger Paul Laubender

http://www.w3.org/2001/XMLSchema#string

Sebastian Gamba

http://www.w3.org/2001/XMLSchema#string

Sebastian Stintzing

http://www.w3.org/2001/XMLSchema#string

Stefano Primo

http://www.w3.org/2001/XMLSchema#string

Volker Heinemann

http://www.w3.org/2001/XMLSchema#string

P2860

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.

Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.

P304

1919-1929

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.15.97

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Clemens Giessen-Jung

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279988486

http://www.w3.org/2001/XMLSchema#string

P698

26161928

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer